Thursday, April 27, 2017
 
 
Company News: Page (1) of 1 - 04/21/17 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook
IBA SA - basic data - update following capital increase dated 21 April 2017

(April 21, 2017)

IBA - DATA CONCERNING TRANSPARENCY

Heading II of the law of May 2, 2007 and the Royal Decree of February 14, 2008

Louvain-la-Neuve, Belgium, April 21, 2017, 11 a.m. - IBA (Ion Beam Applications SA), the world's leading provider of proton therapy solutions for the treatment of cancer, communicates today the basic and additional data as per Article 15 1 al.1 of the Transparency Law, following its capital increase (further to exercises of stock options) dated April 21, 2017.

Communication of the basic data as per Article 15 1 al.1 of the Law

  • Total capital: EUR 41899278.10
  • Total number of securities conferring the voting right: 29852549 (of which 12702489 with VVPR strips)
  • Total number of voting rights (= the denominator): 29852549
  • Total number of securities conferring the voting right, by category: N/A
  • Total number of voting rights, by category: N/A

Communication of the additional data as per Article 15 1 al.2 of the Law

  • Total number of convertible bonds conferring the voting right: 0
  • Total number of rights, materialized or not by certificates, giving the

    right to subscribe to newly issued securities conferring the voting right (e.g. warrants): 509 850
  • Total number of voting rights which would result from the exercise of

    these conversion or subscription rights: 509 850
  • Total number of shares without voting right: 0

Statutory thresholds as per Article 18 of the Law

The applicable thresholds as follows: three percent, five percent, ten percent, fifteen percent and so on by brackets of five percent

About IBA
IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA's proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world.

IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at: www.iba-worldwide.com

For further information, please contact:

IBA

Caroline Hardy
Corporate Legal Counsel
+32 10 201 159
caroline.hardy@iba-group.com

Attachments:

http://www.globenewswire.com/NewsRoom/AttachmentNg/38fc8423-54ef-4a5a-8900-f3055a43f56d


Page: 1


Related Keywords:
Related Sites: HTN - Health Technology Net ,   HTN - Health Technology Net
Related Newsletter: Tutorial Finder ,   Tutorial Finder ,   Review Seeker ,   Review Seeker ,   DMN Newswire Newsletter ,   DMN Newswire Newsletter
 
 
 
 
 
 
 
 
 
 





Our Privacy Policy --- About The Health Technology - Contact Us - Advertise With Us - Privacy Guidelines